SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-057250
Filing Date
2024-05-09
Accepted
2024-05-09 17:04:53
Documents
49
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20240331.htm   iXBRL 10-Q 1764347
2 EX-10.5 virx-ex10_5.htm EX-10.5 59969
3 EX-31.1 virx-ex31_1.htm EX-31.1 10770
4 EX-31.2 virx-ex31_2.htm EX-31.2 10780
5 EX-32.1 virx-ex32_1.htm EX-32.1 5059
6 EX-32.2 virx-ex32_2.htm EX-32.2 4933
  Complete submission text file 0000950170-24-057250.txt   7037415

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240331.xsd EX-101.SCH 1099561
52 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240331_htm.xml XML 1221864
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 24931760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)